Stock 002675 YANTAI DONGCHENG PHARMACEUTICAL GROUP CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Equities

002675

CNE100001DP5

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
14.65 CNY +2.81% Intraday chart for Yantai Dongcheng Pharmaceutical Group Co.,Ltd. +13.30% -20.08%
May. 27 Dongcheng Biochemicals' Unit Gets Nod to Trial Pancreatic Cancer Drug MT
May. 20 Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves the Cash Dividend for the Year 2023 CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Dongcheng Biochemicals' Unit Gets Nod to Trial Pancreatic Cancer Drug
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves the Cash Dividend for the Year 2023
US FDA Grants Clinical Trial Approval for Dongcheng Biochemicals' Injection
Dongcheng Biochemicals' Unit Gets Nod to Trial Tumor Drug
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Dongcheng Biochemicals' Unit Gets Nod to Trial Tumor Drug in Singapore
Dongcheng Pharmaceutical to Buy Liver Drug Rights from Affiliate for 85 Million Yuan
Dongcheng Pharmaceutical Unit to Buy Rights to Tumor-Detecting Drug for 63 Million Yuan; Shares Up 10%
Dongcheng Pharma's Singaporean Unit Gets FDA's Nod to Carry Out Trial on 68GaLNC1007 Injection
Yantai Dongcheng Pharma Unit Secures License for Radioactive Cargo Transport
Dongcheng Pharmaceutical Gets Nod to Trial Tumor Drug in China
Yantai Dongcheng Pharmaceutical's Unit Ties Up With Chinese Physics Institute for Electron Accelerator Development
Yantai Dongcheng Pharma Gets Nod to Trial Prostate Cancer Treatment in China
Dongcheng Pharma Forms Medical Isotopes JV With Germany’s Eckert & Ziegler
Qi Kang Medical Technology Co., Ltd. announced that it has received ?20 million in funding from Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
Dongcheng Biochemicals Unit Gets Nod to Trial Prostate Cancer Drug in Singapore
Dongcheng Biochemicals' Unit Gets Nod to Market Dalteparin Sodium Injection
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Dongcheng Biochemicals Receives Good Manufacturing Practice Certificate from Germany
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 002675 Stock
  4. News Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
  5. Other languages